G-protein-coupled receptors oligomerization: Emerging signaling units and new opportunities for drug design

Current Protein and Peptide Science

Volumn 15, Issue 7, 2014, Pages 648-658

  Tena Campos, Mercè ^a   Ramon, Eva ^a   Rivera, Diana ^a   Borroto Escuela, Dasiel O ^b   Romero Fernández, Wilber ^b   Fuxe, Kjell ^b   Garriga, Pere ^a  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dimers; Disease; Drug design; G protein coupled receptors; Ligand; Oligomerization

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA [B] [1,4] DIAZEPINO [6,7,1 HI] INDOLE; 4 AMINOBUTYRIC ACID B RECEPTOR; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA GALACTOSIDASE; CYM51010; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; EPITOPE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; GALANIN RECEPTOR 1; GHRELIN RECEPTOR; GLUTAMATE RECEPTOR; KAPPA OPIATE RECEPTOR; MELATONIN 1 RECEPTOR; MU OPIATE RECEPTOR; PRAMIPEXOLE; ROPINIROLE; UNCLASSIFIED DRUG; VOLINANSERIN; YELLOW FLUORESCENT PROTEIN; LIGAND;

ARTICLE; BIOINFORMATICS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CHROMATIN IMMUNOPRECIPITATION; COVALENT BOND; CROSS LINKING; DIMERIZATION; DRUG DEPENDENCE; DRUG DESIGN; DRUG TARGETING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HETERODIMERIZATION; HOMODIMERIZATION; HYDROGEN BOND; HYDROPHOBICITY; IMMUNOBLOTTING; LIGAND BINDING; MOLECULAR INTERACTION; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STATIC ELECTRICITY; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84925877618     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203715666140901094248     Document Type: Article

References (82)

1. Springer Reference. Encyclopedia of Molecular Pharmacology: Gprotein- coupled Receptor. http://link.springer.com/referencework entry/10.1007/978-3-540-38918-7_70. (Accessed September 18, 2013).
2. Fredriksson, R.; Lagerstrom, M.C.; Lundin, L.G.; Schioth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63(6), 1256-1272.
3. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289(5480), 739-745.
4. Lundstrom, K. Latest development in drug discovery on G proteincoupled receptors. Curr. Protein Pept. Sci., 2006, 7(5), 465-470.
5. Levoye, A.; Dam, J.; Ayoub, M.A.; Guillaume, J.L.; Couturier, C.; Delagrange, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J., 2006, 25(13), 3012-3023.
6. Chung, S.; Funakoshi, T.; Civelli, O. Orphan GPCR research. Br. J. Pharmacol., 2008, 153(Suppl 1), S339-S346.
7. Southern, C.; Cook, J.M.; Neetoo-Isseljee, Z.; Taylor, D.L.; Kettleborough, C.A.; Merritt, A.; Bassoni, D.L.; Raab, W.J.; Quinn, E.; Wehrman, T.S.; Davenport, A.P.; Brown, A.J.; Green, A.; Wigglesworth, M.J.; Rees, S. Screening beta-arrestin recruitment for the identification of natural ligands for orphan Gprotein- coupled receptors. J. Biomol. Screen, 2013, 18(5), 599-609.
8. Limbird, L.E.; Meyts, P.D.; Lefkowitz, R.J. Beta-adrenergic receptors: evidence for negative cooperativity. Biochem. Biophys. Res. Commun., 1975, 64(4), 1160-1168.
9. Fuxe, K.; Agnati, L.F.; Kohler, C.; Kuonen, D.; Ogren, S.O.; Andersson, K.; Hokfelt, T. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J. Neural Transm., 1981, 51(1-2), 3-37.
10. Agnati, L.F.; Fuxe, K.; Zoli, M.; Rondanini, C.; Ogren, S.O. New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med. Biol., 1982, 60(4), 183-190.
11. Fuxe, K.; Agnati, L.F.; Benfenati, F.; Celani, M.; Zini, I.; Zoli, M.; Mutt, V. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. Neural Transm. Suppl., 1983, 18, 165-179.
12. Jones, K.A.; Borowsky, B.; Tamm, J.A.; Craig, D.A.; Durkin, M.M.; Dai, M.; Yao, W.J.; Johnson, M.; Gunwaldsen, C.; Huang, L.Y.; Tang, C.; Shen, Q.; Salon, J.A.; Morse, K.; Laz, T.; Smith, K.E.; Nagarathnam, D.; Noble, S.A.; Branchek, T.A.; Gerald, C. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature, 1998, 396(6712), 674-679.
13. Borroto-Escuela, D.O.; Brito, I.; Romero-Fernandez, W.; Di Palma, M.; Oflijan, J.; Skieterska, K.; Duchou, J.; Van Craenenbroeck, K.; Suárez-Boomgaard, D.; Rivera, A.; Guidolin, D.; Agnati, L.F.; Fuxe, K. The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int. J. Mol. Sci., 2014, In Press.
14. Levoye, A.; Dam, J.; Ayoub, M.A.; Guillaume, J.L.; Jockers, R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep., 2006, 7(11), 1094-1098.
15. Breitwieser, G.E. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ. Res., 2004, 94(1), 17-27.
16. Hern, J.A.; Baig, A.H.; Mashanov, G.I.; Birdsall, B.; Corrie, J.E.; Lazareno, S.; Molloy, J.E.; Birdsall, N.J. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(6), 2693-2698.
17. Lambert, N.A. GPCR dimers fall apart. Sci. Signal, 2010, 3(115), pe12.
18. Herrick-Davis, K.; Grinde, E.; Cowan, A.; Mazurkiewicz, J.E. Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol. Pharmacol., 2013, 84(4), 630-642.
19. Patowary, S.; Alvarez-Curto, E.; Xu, T.R.; Holz, J.D.; Oliver, J.A.; Milligan, G.; Raicu, V. The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochem. J., 2013, 452(2), 303-312.
20. Uberti, M.A.; Hague, C.; Oller, H.; Minneman, K.P.; Hall, R.A. Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. J. Pharmacol. Exp. Ther., 2005, 313(1), 16-23.
21. Salim, K.; Fenton, T.; Bacha, J.; Urien-Rodriguez, H.; Bonnert, T.; Skynner, H.A.; Watts, E.; Kerby, J.; Heald, A.; Beer, M.; McAllister, G.; Guest, P.C. Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J. Biol. Chem., 2002, 277(18), 15482-15485.
22. Pin, J.P.; Neubig, R.; Bouvier, M.; Devi, L.; Filizola, M.; Javitch, J.A.; Lohse, M.J.; Milligan, G.; Palczewski, K.; Parmentier, M.; Spedding, M. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev., 2007, 59(1), 5-13.
23. Soderberg, O.; Gullberg, M.; Jarvius, M.; Ridderstrale, K.; Leuchowius, K.J.; Jarvius, J.; Wester, K.; Hydbring, P.; Bahram, F.; Larsson, L.G.; Landegren, U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods, 2006, 3(12), 995-1000.
24. Borroto-Escuela, D.O.; Van Craenenbroeck, K.; Romero- Fernandez, W.; Guidolin, D.; Woods, A.S.; Rivera, A.; Haegeman, G.; Agnati, L.F.; Tarakanov, A.O.; Fuxe, K. Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions. Biochem. Biophys. Res. Commun., 2011, 404(4), 928-934.
25. Trifilieff, P.; Rives, M.L.; Urizar, E.; Piskorowski, R.A.; Vishwasrao, H.D.; Castrillon, J.; Schmauss, C.; Slattman, M.; Gullberg, M.; Javitch, J.A. Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2- adenosine A2A receptor complexes in the striatum. BioTechniques, 2011, 51(2), 111-118.
26. Borroto-Escuela, D.O.; Romero-Fernandez, W.; Garriga, P.; Ciruela, F.; Narvaez, M.; Tarakanov, A.O.; Palkovits, M.; Agnati, L.F.; Fuxe, K. G protein-coupled receptor heterodimerization in the brain. Meth. Enzymol., 2013, 521, 281-294.
27. Lichtarge, O.; Bourne, H.R.; Cohen, F.E. An evolutionary trace method defines binding surfaces common to protein families. J. Mol. Biol., 1996, 257(2), 342-358.
28. Gobel, U.; Sander, C.; Schneider, R.; Valencia, A. Correlated mutations and residue contacts in proteins. Proteins, 1994, 18(4), 309-317.
29. Nemoto, W.; Fukui, K.; Toh, H. GRIP: a server for predicting interfaces for GPCR oligomerization. J. Recept. Signal Transduct. Res., 2009, 29(6), 312-317.
30. Tarakanov, A.O.; Fuxe, K.G. The triplet puzzle of homologies in receptor heteromers exists also in other types of protein-protein interactions. J. Mol. Neurosci., 2011, 44(3), 173-177.
31. Borroto-Escuela, D.O.; Narvaez, M.; Marcellino, D.; Parrado, C.; Narvaez, J.A.; Tarakanov, A.O.; Agnati, L.F.; Diaz-Cabiale, Z.; Fuxe, K. Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem. Biophys. Res. Commun., 2010, 393(4), 767-772.
32. Borroto-Escuela, D.O.; Romero-Fernandez, W.; Tarakanov, A.O.; Marcellino, D.; Ciruela, F.; Agnati, L.F.; Fuxe, K. Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers. Biochem. Biophys. Res. Commun., 2010, 401(4), 605-610.
33. Nygaard, R.; Zou, Y.; Dror, R.O.; Mildorf, T.J.; Arlow, D.H.; Manglik, A.; Pan, A.C.; Liu, C.W.; Fung, J.J.; Bokoch, M.P.; Thian, F.S.; Kobilka, T.S.; Shaw, D.E.; Mueller, L.; Prosser, R.S.; Kobilka, B.K. The dynamic process of beta(2)-adrenergic receptor activation. Cell, 2013, 152(3), 532-542.
34. Rodriguez, D.; Gutierrez-de-Teran, H., Characterization of the homodimerization interface and functional hotspots of the CXCR4 chemokine receptor. Proteins, 2012, 80(8), 1919-1928.
35. Zeng, F.Y.; Wess, J. Identification and molecular characterization of m3 muscarinic receptor dimers. J. Biol. Chem., 1999, 274(27), 19487-19497.
36. Berthouze, M.; Rivail, L.; Lucas, A.; Ayoub, M.A.; Russo, O.; Sicsic, S.; Fischmeister, R.; Berque-Bestel, I.; Jockers, R.; Lezoualc'h, F. Two transmembrane Cys residues are involved in 5- HT4 receptor dimerization. Biochem. Biophys. Res. Commun., 2007, 356(3), 642-647.
37. Klco, J.M.; Lassere, T.B.; Baranski, T.J. C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J. Biol. Chem., 2003, 278(37), 35345-35353.
38. Hu, J.; Thor, D.; Zhou, Y.; Liu, T.; Wang, Y.; McMillin, S.M.; Mistry, R.; Challiss, R.A.; Costanzi, S.; Wess, J. Structural aspects of M(3) muscarinic acetylcholine receptor dimer formation and activation. FASEB J., 2012, 26(2), 604-616.
39. Woods, A.S.; Ferre, S. Amazing stability of the arginine-phosphate electrostatic interaction. J. Proteome Res., 2005, 4(4), 1397-1402.
40. Ciruela, F.; Burgueno, J.; Casado, V.; Canals, M.; Marcellino, D.; Goldberg, S.R.; Bader, M.; Fuxe, K.; Agnati, L.F.; Lluis, C.; Franco, R.; Ferre, S.; Woods, A.S. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem., 2004, 76(18), 5354-5363.
41. Borroto-Escuela, D.O.; Marcellino, D.; Narvaez, M.; Flajolet, M.; Heintz, N.; Agnati, L.; Ciruela, F.; Fuxe, K. A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R. B Biochem. Biophys. Res. Commun.,2010, 394(1), 222-227.
42. Borroto-Escuela, D.O.; Romero-Fernandez, W.; Tarakanov, A.O.; Gomez-Soler, M.; Corrales, F.; Marcellino, D.; Narvaez, M.; Frankowska, M.; Flajolet, M.; Heintz, N.; Agnati, L.F.; Ciruela, F.; Fuxe, K. Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun., 2010, 402(4), 801-807.
43. Navarro, G.; Ferre, S.; Cordomi, A.; Moreno, E.; Mallol, J.; Casado, V.; Cortes, A.; Hoffmann, H.; Ortiz, J.; Canela, E.I.; Lluis, C.; Pardo, L.; Franco, R.; Woods, A.S. Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J. Biol. Chem., 2010, 285(35), 27346-27359.
44. Lee, S.P.; O'Dowd, B.F.; Rajaram, R.D.; Nguyen, T.; George, S.R. D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry, 2003, 42(37), 11023-11031.
45. Fotiadis, D.; Liang, Y.; Filipek, S.; Saperstein, D.A.; Engel, A.; Palczewski, K., Atomic-force microscopy: Rhodopsin dimers in native disc membranes. Nature, 2003, 421(6919), 127-128.
46. Breit, A.; Lagace, M.; Bouvier, M. Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J. Biol. Chem., 2004, 279(27), 28756-28765.
47. Bulenger, S.; Marullo, S.; Bouvier, M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci., 2005, 26(3), 131-137.
48. Franco, R. G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. Br. J. Pharmacol., 2009, 158(1), 23-31.
49. Levoye, A.; Jockers, R.; Ayoub, M.A.; Delagrange, P.; Savaskan, E.; Guillaume, J.L. Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors. Chronobiol. Int., 2006, 23(1-2), 419-426.
50. Rozenfeld, R.; Devi, L.A. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mudelta opioid receptor heterodimers. FASEB J., 2007, 21(10), 2455-2465.
51. Trincavelli, M.L.; Daniele, S.; Orlandini, E.; Navarro, G.; Casado, V.; Giacomelli, C.; Nencetti, S.; Nuti, E.; Macchia, M.; Huebner, H.; Gmeiner, P.; Rossello, A.; Lluis, C.; Martini, C. A new D(2) dopamine receptor agonist allosterically modulates A(2A) adenosine receptor signalling by interacting with the A(2A)/D(2) receptor heteromer. Cell Signal, 2012, 24(4), 951-960.
52. Ferre, S.; O'Connor, W.T.; Snaprud, P.; Ungerstedt, U.; Fuxe, K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience, 1994, 63(3), 765-773.
53. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U. S. A., 1991, 88(16), 7238-7241.
54. Kargl, J.; Balenga, N.; Parzmair, G.P.; Brown, A.J.; Heinemann, A.; Waldhoer, M. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J. Biol. Chem., 2012, 287(53), 44234-44248.
55. Maggio, R.; Millan, M.J. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr. Opin. Pharmacol., 2010, 10(1), 100-107.
56. Frey, A.J.; Ibrahim, S.; Gleim, S.; Hwa, J.; Smyth, E.M. Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. J. Lipid Res., 2013, 54(6), 1678-1690.
57. Lee, S.P.; So, C.H.; Rashid, A.J.; Varghese, G.; Cheng, R.; Lanca, A.J.; O'Dowd, B.F.; George, S.R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 2004, 279(34), 35671-35678.
58. Ehrlich, A.T.; Furuyashiki, T.; Kitaoka, S.; Kakizuka, A.; Narumiya, S. Prostaglandin E Receptor EP1 Forms a Complex with Dopamine D1 Receptor and Directs D1-Induced cAMP Production to Adenylyl Cyclase 7 through Mobilizing Gbetagamma Subunits in Human Embryonic Kidney 293T Cells. Mol. Pharmacol., 2013, 84(3), 476-486.
59. Gupta, A.; Mulder, J.; Gomes, I.; Rozenfeld, R.; Bushlin, I.; Ong, E.; Lim, M.; Maillet, E.; Junek, M.; Cahill, C.M.; Harkany, T.; Devi, L.A. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci. Signal, 2010, 3(131), ra54.
60. Schelshorn, D.; Joly, F.; Mutel, S.; Hampe, C.; Breton, B.; Mutel, V.; Lutjens, R. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol., 2012, 81(3), 309-318.
61. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; Lopez-Gimenez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452(7183), 93-97.
62. Kachroo, A.; Orlando, L.R.; Grandy, D.K.; Chen, J.F.; Young, A.B.; Schwarzschild, M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci., 2005, 25(45), 10414-10419.
63. Cabello, N.; Gandia, J.; Bertarelli, D.C.; Watanabe, M.; Lluis, C.; Franco, R.; Ferre, S.; Lujan, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higherorder oligomers in living cells. J. Neurochem., 2009, 109(5), 1497-1507.
64. Antonelli, T.; Fuxe, K.; Tomasini, M.C.; Mazzoni, E.; Agnati, L.F.; Tanganelli, S.; Ferraro, L. Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. Prog. Neurobiol., 2007, 83(2), 92-109.
65. Cunningham, K.A.; Anastasio, N.C.; Fox, R.G.; Stutz, S.J.; Bubar, M.J.; Swinford, S.E.; Watson, C.S.; Gilbertson, S.R.; Rice, K.C.; Rosenzweig-Lipson, S.; Moeller, F.G. Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem. Neurosci., 2013, 4(1), 110-121.
66. Gomes, I.; Fujita, W.; Gupta, A.; Saldanha, A.S.; Negri, A.; Pinello, C.E.; Roberts, E.; Filizola, M.; Hodder, P.; Devi, L.A. Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc. Natl. Acad. Sci. U. S. A., 2013, 110(29), 12072-12077.
67. Akgun, E.; Javed, M.I.; Lunzer, M.M.; Smeester, B.A.; Beitz, A.J.; Portoghese, P.S. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. Proc. Natl. Acad. Sci. U. S. A., 2013, 110(28), 11595-11599.
68. van Rijn, R.M.; Harvey, J.H.; Brissett, D.I.; DeFriel, J.N.; Whistler, J.L. Novel screening assay for the selective detection of G-proteincoupled receptor heteromer signaling. J. Pharmacol. Exp. Ther., 2013, 344(1), 179-188.
69. Yuan, Y.; Arnatt, C.K.; El-Hage, N.; Dever, S.M.; Jacob, J.C.; Selley, D.E.; Hauser, K.F.; Zhang, Y. A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities. Medchemcomm, 2013, 4(5), 847-851.
70. Hiller, C.; Kuhhorn, J.; Gmeiner, P. Class A G-Protein-Coupled Receptor (GPCR) Dimers and Bivalent Ligands. J. Med. Chem., 2013, 56(17), 6542-6559.
71. Gorinski, N.; Kowalsman, N.; Renner, U.; Wirth, A.; Reinartz, M.T.; Seifert, R.; Zeug, A.; Ponimaskin, E.; Niv, M.Y. Computational and experimental analysis of the transmembrane domain 4/5 dimerization interface of the serotonin 5-HT(1A) receptor. Mol. Pharmacol., 2012, 82(3), 448-463.
72. Fanelli, F.; Felline, A. Dimerization and ligand binding affect the structure network of A(2A) adenosine receptor. Biochim. Biophys. Acta, 2011, 1808(5), 1256-1266.
73. Carrillo, J.J.; Lopez-Gimenez, J.F.; Milligan, G. Multiple interactions between transmembrane helices generate the oligomeric alpha1b-adrenoceptor. Mol. Pharmacol., 2004, 66(5), 1123-1137.
74. Hernanz-Falcon, P.; Rodriguez-Frade, J.M.; Serrano, A.; Juan, D.; del Sol, A.; Soriano, S.F.; Roncal, F.; Gomez, L.; Valencia, A.; Martinez, A.C.; Mellado, M. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat. Immunol., 2004, 5(2), 216-223.
75. Trettel, F.; Di Bartolomeo, S.; Lauro, C.; Catalano, M.; Ciotti, M.T.; Limatola, C. Ligand-independent CXCR2 dimerization. J. Biol. Chem., 2003, 278(42), 40980-40988.
76. Juhasz, J.R.; Hasbi, A.; Rashid, A.J.; So, C.H.; George, S.R.; O'Dowd, B.F. Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Eur. J. Pharmacol., 2008, 581(3), 235-243.
77. Filizola, M.; Weinstein, H. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers, 2002, 66(5), 317-325.
78. McMillin, S.M.; Heusel, M.; Liu, T.; Costanzi, S.; Wess, J., Structural basis of M3 muscarinic receptor dimer/oligomer formation. J. Biol. Chem., 2011, 286(32), 28584-28598.
79. Casciari, D.; Dell'Orco, D.; Fanelli, F. Homodimerization of neurotensin 1 receptor involves helices 1, 2, and 4: insights from quaternary structure predictions and dimerization free energy estimations. J. Chem. Inf. Model., 2008, 48(8), 1669-1678.
80. Fanelli, F.; Mauri, M.; Capra, V.; Raimondi, F.; Guzzi, F.; Ambrosio, M.; Rovati, G.E.; Parenti, M. Light on the structure of thromboxane A(2)receptor heterodimers. Cell Mol. Life Sci., 2011, 68(18), 3109-3120.
81. Kota, P.; Reeves, P.J.; Rajbhandary, U.L.; Khorana, H.G. Opsin is present as dimers in COS1 cells: identification of amino acids at the dimeric interface. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(9), 3054-3059.
82. Borroto-Escuela, D.O.; Garcia-Negredo, G.; Garriga, P.; Fuxe, K.; Ciruela, F. The M(5) muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization. Biochim. Biophys. Acta, 2010, 1803(7), 813-825.